TrialCNS drugs2025

Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Results of a Long-Term, Phase 3, Open-Label Extension Trial.

Robert L Findling et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.